Week in Review: The Latest from PhRMA

The Value of Biopharmaceutical Innovation:  The continued development of new treatments and cures not only contributes valuable knowledge to the research and development process, it also improves patients’ lives, advances medical innovation, makes health care better and fuels economic growth. Learn more about the impact of biopharmaceutical innovation here.

Q&A with RxEconomics LLC: In the latest Ask About Adherence series, we feature a Q&A with RxEconomics President and CEO M. Christopher Roebuck  about medication adherence and economic evaluation of prescription drugs.

The Clinical Pathways Debate: In this guest blog, Alan Balch, the CEO of the National Patient Advocate Foundation, tells us about clinical pathways and what they mean for patients and their treatment options .

The Case for Sharing Truthful, Non-Misleading Information: Earlier this week, The Wall Street Journal editorialized on the importance of free speech in the context of sharing scientific and medical information. The editorial calls on the U.S. Food and Drug Administration to update its regulatory framework for biopharmaceutical communications with health care professionals so that physicians can make informed prescribing decisions. Find out more here.

Medicare Monday: Check out this week’s post, which busts a popular myth about negotiation in Medicare Part D, explaining how powerful Part D purchasers negotiate discounts and rebates directly with manufacturers that save money for both beneficiaries and taxpayers.